NEWS IN BRIEF

Alcami supporting commercial supply of Flexion’s first FDA-approved product

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/svengine)
(Image: Getty/svengine)
Alcami began work on Flexion Therapeutics's ZILRETTA in the fall of 2014 and today announced that it will further support commercial supply of the product, which is approved for the treatment of OA-related knee pain.

The contract development and manufacturing organization (CDMO) is expanding deployment of its “Extended Workbench” for the continuing manufacturing and development of ZILRETTA (triamcinolone acetonide extended-release injectable suspension).

Flexion initially used Alcami's ​“Extended Workbench” – a full-time equivalent (FTE) service program – to support Phase II clinical trials through commercial launch. Moving forward, the MA-based biopharmaceutical company will use the program for release and stability testing of commercial batches.

ZILRETTA is Flexion’s the first US Food and Drug Administration (FDA) approved product and was approved for the treatment of OA-related knee pain on October 6, 2017. It officially launched nationwide in late November of 2017.

"Our versatile Extended Workbench solution was an excellent fit for our partners at Flexion, whose accelerated timeline, robust clinical trial program, and specific testing requirements mandated dedicated laboratory resources to get their product to market,"​ said Alcami Chief Commercial Officer, Syed T. Husain in a press release.

Related product

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers

Follow us

Products

View more